PT  - JOURNAL ARTICLE
AU  - Butzin-Dozier, Zachary
AU  - Ji, Yunwen
AU  - Coyle, Jeremy
AU  - Malenica, Ivana
AU  - Rogawski McQuade, Elizabeth T.
AU  - Grembi, Jessica Anne
AU  - Platts-Mills, James A.
AU  - Houpt, Eric R.
AU  - Graham, Jay P.
AU  - Ali, Shahjahan
AU  - Rahman, Md Ziaur
AU  - Alauddin, Mohammad
AU  - Famida, Syeda L.
AU  - Akther, Salma
AU  - Hossen, Md. Saheen
AU  - Mutsuddi, Palash
AU  - Shoab, Abul K.
AU  - Rahman, Mahbubur
AU  - Islam, Md. Ohedul
AU  - Miah, Rana
AU  - Taniuchi, Mami
AU  - Liu, Jie
AU  - Alauddin, Sarah
AU  - Stewart, Christine P.
AU  - Luby, Stephen P.
AU  - Colford, John M.
AU  - Hubbard, Alan E.
AU  - Mertens, Andrew N.
AU  - Lin, Audrie
TI  - Treatment Heterogeneity of Water, Sanitation, Hygiene, and Nutrition Interventions on Child Growth by Environmental Enteric Dysfunction and Pathogen Status for Young Children in Bangladesh
AID  - 10.1101/2024.03.21.24304684
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.21.24304684
4099  - http://medrxiv.org/content/early/2024/03/26/2024.03.21.24304684.short
4100  - http://medrxiv.org/content/early/2024/03/26/2024.03.21.24304684.full
AB  - Background Water, sanitation, hygiene (WSH), nutrition (N), and combined (N+WSH) interventions are often implemented by global health organizations, but WSH interventions may insufficiently reduce pathogen exposure, and nutrition interventions may be modified by environmental enteric dysfunction (EED), a condition of increased intestinal permeability and inflammation. This study investigated the heterogeneity of these treatments’ effects based on individual pathogen and EED biomarker status with respect to child linear growth.Methods We applied cross-validated targeted maximum likelihood estimation and super learner ensemble machine learning to assess the conditional treatment effects in subgroups defined by biomarker and pathogen status. We analyzed treatment (N+WSH, WSH, N, or control) randomly assigned in-utero, child pathogen and EED data at 14 months of age, and child LAZ at 28 months of age. We estimated the difference in mean child length for age Z-score (LAZ) under the treatment rule and the difference in stratified treatment effect (treatment effect difference) comparing children with high versus low pathogen/biomarker status while controlling for baseline covariates.Results We analyzed data from 1,522 children, who had median LAZ of -1.56. We found that myeloperoxidase (N+WSH treatment effect difference 0.0007 LAZ, WSH treatment effect difference 0.1032 LAZ, N treatment effect difference 0.0037 LAZ) and Campylobacter infection (N+WSH treatment effect difference 0.0011 LAZ, WSH difference 0.0119 LAZ, N difference 0.0255 LAZ) were associated with greater effect of all interventions on growth. In other words, children with high myeloperoxidase or Campylobacter infection experienced a greater impact of the interventions on growth. We found that a treatment rule that assigned the N+WSH (LAZ difference 0.23, 95% CI (0.05, 0.41)) and WSH (LAZ difference 0.17, 95% CI (0.04, 0.30)) interventions based on EED biomarkers and pathogens increased predicted child growth compared to the randomly allocated intervention.Conclusions These findings indicate that EED biomarker and pathogen status, particularly Campylobacter and myeloperoxidase (a measure of gut inflammation), may be related to impact of N+WSH, WSH, and N interventions on child linear growth.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Global Development grants [OPPGD759 and OPP1165144] from the Bill & Melinda Gates Foundation to the University of California, Berkeley and by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health [grant number K01AI136885 to AL].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The primary caregiver of each child provided written informed consent prior to enrollment. Human subjects protection committees at icddr,b, the University of California, Berkeley, and Stanford University approved the study protocols. The parent trial was registered at ClinicalTrials.gov (NCT01590095) and a safety monitoring committee convened by icddr,b oversaw the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data and analysis scripts are publicly available via https://osf.io/cg8dv/